📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Lupin's Ankleshwar Facility Receives US FDA Form-483 with 2 Observations
The U.S. FDA concluded a six-day inspection at Lupin's manufacturing facility in Ankleshwar, India, on March 07, 2026. The inspection resulted in the issuance of a Form-483 with two observations regarding manufacturing practices. Lupin has stated it will address these observations and respond to the regulator within the stipulated timeframe to ensure CGMP compliance. While the number of observations is low, the impact depends on their technical severity and the company's ability to remediate them quickly.
Key Highlights
U.S. FDA inspection conducted at the Ankleshwar facility from March 02 to March 07, 2026.
The inspection concluded with the issuance of a Form-483 containing 2 observations.
Lupin is required to respond to the U.S. FDA within the stipulated timeframe to address findings.
Company maintains commitment to CGMP standards across all manufacturing facilities.
💼 Action for Investors
Investors should monitor for the final classification of the inspection (VAI or OAI) as significant observations could lead to regulatory escalations. The low number of observations is generally manageable, but the specific nature of the findings will determine the long-term impact on US exports.
Lupin Delays Acquisition of VISUfarma B.V. to April 2026
Lupin Limited has announced a timeline extension for the acquisition of VISUfarma B.V. by its subsidiary, Nanomi B.V. The transaction, which involves acquiring 100% of the share capital, was previously expected to conclude by February 28, 2026. The company now anticipates completion in April 2026, pending the satisfaction of specific closing conditions. This acquisition is a strategic move to strengthen Lupin's presence in the European pharmaceutical market.
Key Highlights
Acquisition of 100% share capital of Netherlands-based VISUfarma B.V. by Lupin's subsidiary Nanomi B.V.
Completion timeline extended from February 28, 2026, to April 2026.
Delay is attributed to the ongoing fulfillment of specific closing conditions.
Follows previous regulatory updates provided on September 29, 2025, and December 30, 2025.
💼 Action for Investors
Investors should view this as a minor procedural delay rather than a deal cancellation. Monitor for the final completion announcement in April 2026 to assess the impact on Lupin's international revenue growth.
Lupin Receives US FDA EIR with Satisfactory VAI Status for Goa Facility
Lupin Limited has successfully received the Establishment Inspection Report (EIR) from the US FDA for its Goa manufacturing facility. The report follows an 11-day inspection conducted from November 10 to November 21, 2025. The facility has been assigned a Voluntary Action Indicated (VAI) classification, which is considered a satisfactory regulatory outcome. This clearance is crucial for Lupin as it ensures the continued supply and potential for new product approvals from this key export site to the US market.
Key Highlights
Received US FDA EIR for the Goa facility with a satisfactory VAI classification.
The inspection was conducted over an 11-day period from November 10 to November 21, 2025.
VAI status indicates that the facility meets regulatory standards despite minor observations.
This clearance supports Lupin's global supply chain and US market growth strategy.
💼 Action for Investors
This is a positive development that removes a significant regulatory overhang for the Goa plant. Investors should monitor for potential new product approvals from this site that may have been pending the inspection outcome.
Lupin Ranks #1 Globally in Pharma with 91/100 Score in S&P ESG Assessment 2025
Lupin has achieved the top global rank in the pharmaceutical sector in the 2025 S&P Global Corporate Sustainability Assessment (CSA) with a score of 91 out of 100. This score places Lupin in the top 1% of over 9,200 companies evaluated across 59 industries worldwide. Additionally, the company has been recognized as the leader across all sectors in India, surpassing both domestic and international peers. This marks Lupin's third consecutive year of inclusion in the S&P Sustainability Yearbook, reflecting strong governance and environmental stewardship.
Key Highlights
Achieved a score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment (CSA)
Ranked No. 1 globally in the pharmaceutical industry and No. 1 across all sectors in India
Placed within the top 1% of more than 9,200 companies assessed globally
Included in the Sustainability Yearbook 2026 for the third consecutive year
One of only 848 companies to earn Yearbook inclusion out of 9,200+ assessed
💼 Action for Investors
This recognition enhances Lupin's appeal to institutional and ESG-focused investors, potentially leading to increased capital inflows. Investors should consider this a positive indicator of the company's long-term operational resilience and governance standards.
Lupin Ranks #1 Globally in Pharma with 91/100 S&P ESG Score
Lupin Limited has achieved the top global rank in the pharmaceutical sector in the S&P Global Corporate Sustainability Assessment 2025. The company secured a score of 91 out of 100, placing it in the top 1% of companies worldwide. Notably, Lupin also ranked as the leader across all sectors in India, surpassing both domestic and international peers. This marks the third consecutive year Lupin has been included in the S&P Sustainability Yearbook, which features only 848 companies out of over 9,200 assessed.
Key Highlights
Achieved a score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025.
Ranked #1 globally in the pharmaceutical industry and #1 across all sectors in India.
Placed within the top 1% of companies worldwide for sustainability performance.
Included in the S&P Sustainability Yearbook 2026 for the third consecutive year.
Outperformed over 9,200 companies assessed across 59 different industries globally.
💼 Action for Investors
Investors should view this as a positive indicator of Lupin's strong governance and risk management, which often attracts long-term institutional capital. It reinforces the company's premium positioning in the ESG-conscious investment landscape.
Lupin Faces GST Inspection and Search at Registered Office in Mumbai
Lupin Limited has reported that the Maharashtra Goods & Service Tax Department initiated an inspection and search at its registered office on February 25, 2026. The search, conducted under Section 67 of the MGST Act, 2017, pertains to the verification of GST payments and Input Tax Credit (ITC) claims. The company is currently cooperating with officials and has stated that there is no immediate impact on its financial or operational activities. Investors should note that such inspections are procedural but can lead to future tax demands if discrepancies are found.
Key Highlights
GST Department initiated search proceedings at Lupin's Mumbai office on February 25, 2026, at 11:50 AM.
The inspection is being conducted under Section 67 of the Maharashtra GST Act, 2017.
Authorities are seeking documents specifically related to GST payments and Input Tax Credit (ITC) claims.
Lupin reports no current quantifiable impact on its financial or operational performance.
The company is extending full cooperation and providing all necessary documentation to the tax officials.
💼 Action for Investors
Investors should monitor for subsequent updates regarding any potential tax demands or litigation resulting from this search. No immediate action is required as operations remain unaffected, but tax-related developments can impact future cash flows.
Lupin Launches Brivaracetam Oral Solution in US Targeting $135 Million Market
Lupin Limited has received US FDA approval and commenced the launch of Brivaracetam Oral Solution (10 mg/mL) in the United States. The product is a generic equivalent of UCB's Briviact, used for treating partial-onset seizures in patients aged 1 month and older. According to IQVIA data, the annual sales for this product in the US were approximately USD 135 million as of December 2025. This launch further strengthens Lupin's presence in the US Central Nervous System (CNS) therapeutic segment.
Key Highlights
Received US FDA approval for Brivaracetam Oral Solution 10 mg/mL ANDA
Product is the bioequivalent to Briviact Oral Solution by UCB, Inc.
Targets a US market size estimated at USD 135 million per IQVIA MAT Dec 2025 data
Indicated for partial-onset seizures in patients 1 month of age and older
Immediate launch initiated in the United States market following approval
💼 Action for Investors
Investors should monitor the ramp-up of this product as it contributes to Lupin's high-margin US generic portfolio. The launch is a positive development for the company's CNS segment and overall US revenue growth.
Lupin Receives European Commission Approval for Biosimilar Ranibizumab (Ranluspec™)
Lupin has received marketing authorization from the European Commission for its biosimilar Ranibizumab, branded as Ranluspec™, available in vials and pre-filled syringes. The approval covers critical ophthalmic indications including wet age-related macular degeneration and diabetic macular edema. Lupin has partnered with Sandoz for commercialization across the European Union (excluding Germany) and with both Sandoz and Biogaran in France. This milestone validates Lupin's biotechnology capabilities and strengthens its portfolio in the high-growth biosimilars market.
Key Highlights
European Commission approval granted for Ranluspec™ (biosimilar Ranibizumab) for multiple ophthalmic indications.
Approval includes both vial and pre-filled syringe formats, enhancing delivery options for healthcare providers.
Strategic commercialization partnership formed with Sandoz for the EU market, excluding Germany.
Specific dual-partner commercialization strategy implemented for the French market with Sandoz and Biogaran.
The product targets high-value therapeutic areas such as neovascular (wet) age-related macular degeneration and diabetic macular edema.
💼 Action for Investors
Investors should view this as a significant positive development that expands Lupin's high-margin biologics portfolio in regulated markets. Monitor the commercial rollout and subsequent market share gains in Europe to assess long-term revenue impact.
Lupin Partners with Spektus to Launch Novel Antidepressant DeslaFlex in Canada
Lupin Limited has signed a strategic license and supply agreement with Spektus Pharma to commercialize DeslaFlex™, a novel antidepressant, in the Canadian market. DeslaFlex™ utilizes the proprietary Flexitab™ oral drug-delivery platform to treat Major Depressive Disorder with enhanced dosing flexibility. This partnership leverages Lupin's established commercial infrastructure in Canada to expand its Central Nervous System (CNS) portfolio. The collaboration is part of Lupin's broader strategy to introduce value-added, physician-endorsed specialty therapies in developed markets.
Key Highlights
Exclusive license and supply agreement for the commercialization of DeslaFlex™ in Canada.
Targeted at Major Depressive Disorder using the proprietary Flexitab™ drug-delivery platform.
Strengthens Lupin's CNS portfolio and global specialty business footprint.
Lupin maintains a global presence with 15 manufacturing sites and 7 research centers.
The agreement marks Spektus Pharma's transition from development to commercial execution.
💼 Action for Investors
Investors should monitor the commercial rollout and market share gains of DeslaFlex™ in Canada as it represents a high-margin specialty product addition. This move reinforces Lupin's growth potential in the CNS segment within developed markets.
Anand Kripalu Joins Lupin Board as Independent Director
Lupin Limited has appointed Anand Kripalu as an Independent Director to its Board, effective February 13, 2026. Kripalu brings over 30 years of leadership experience from the FMCG sector, having served as MD and Global CEO of EPL Limited and CEO of Diageo India. His extensive background includes 20 years at Unilever and leadership roles at Mondelez International. This appointment is expected to strengthen Lupin's strategic oversight and global market positioning.
Key Highlights
Anand Kripalu appointed as Independent Director with over 30 years of FMCG leadership experience.
Previously served as Managing Director and Global CEO of EPL Limited until December 31, 2025.
Held senior leadership roles at Diageo India (MD & CEO) and Mondelez International (President - India & SE Asia).
Currently serves on the boards of Swiggy Limited and United Breweries Limited.
Educational background includes degrees from IIT Madras and IIM Calcutta, plus an AMP from Wharton.
💼 Action for Investors
Investors should view this as a positive corporate governance move that adds significant consumer-market expertise to the board. No immediate action is required, but the appointment may help refine Lupin's domestic and global branding strategies.
Lupin Shareholders Approve Appointment of Anand Kripalu as Independent Director
Lupin Limited has announced that its shareholders have approved the appointment of Mr. Anand Kripalu as an Independent Director through a special resolution. The voting, conducted via postal ballot, saw a high participation rate with 90.17% of total shares represented. The resolution passed with a significant majority, as 96.54% of the total votes cast were in favor of the appointment. This move strengthens the company's board governance with the addition of an experienced professional.
Key Highlights
Special resolution for the appointment of Anand Kripalu passed with 96.54% votes in favor.
Total voter turnout was robust at 90.17%, representing 411,905,910 shares.
Promoter and Promoter Group voted 100% in favor of the resolution with 214.2 million votes.
Public Institutional shareholders supported the move with 92.76% of their votes cast in favor.
The appointment was finalized on February 13, 2026, following the conclusion of the remote e-voting period.
💼 Action for Investors
Investors should view this as a positive step in strengthening corporate governance. No immediate portfolio action is required, but the addition of experienced independent directors is generally favorable for long-term oversight.
Lupin Q3 FY26: Net Profit jumps 38% to ₹1,176 Cr; EBITDA margins expand to 31.1%
Lupin reported a robust performance for Q3 FY26, with consolidated revenue growing 26% YoY to ₹7,101 crore, primarily driven by a 46% surge in the US market. EBITDA margins saw a significant expansion to 31.1% from 24.3% in the previous year, reflecting a superior product mix and operational efficiencies. The US business achieved a record quarterly high of $350 million, supported by key launches like gRisperdal Consta. While India growth was moderate at 6%, the company maintained its leadership in chronic segments and improved its net cash position.
Key Highlights
Consolidated Sales grew 26% YoY to ₹71,005 mn, while EBITDA surged 62% YoY to ₹22,095 mn.
US sales reached a record $350 mn, growing 46% YoY, driven by complex generic launches and base business momentum.
EBITDA margins expanded significantly to 31.1% compared to 24.3% in Q3 FY25.
The company is now in a net cash position with a Net Debt to Equity ratio of -0.14.
Received US FDA approval for Armlupeg (biosimilar) and successful inspection outcomes (NAI/VAI) for Nagpur and Aurangabad sites.
💼 Action for Investors
Investors should view this as a strong performance, particularly the massive margin expansion and record US sales. The stock remains a key pick in the pharma sector as it successfully pivots toward complex generics and biosimilars.
Lupin Q3 FY26 Results: PAT Up 37% YoY to ₹1,181 Cr; US Sales Surge 54%
Lupin reported a robust performance for Q3 FY26, with consolidated sales growing 26.4% YoY to ₹7,101 crore, driven by record US sales of $350 million. EBITDA margins saw a significant expansion of 840 bps YoY to 33.5%, although they moderated slightly from the previous quarter. Despite a one-time exceptional charge of ₹427 crore, Profit After Tax (PAT) grew 37.4% YoY to ₹1,181 crore. The company remains net debt-free with a strong cash position of ₹2,879 crore.
Key Highlights
Consolidated Sales grew 26.4% YoY to ₹71,005 Mn, led by a 54% surge in US revenue.
EBITDA increased 68.6% YoY to ₹23,766 Mn with margins expanding to 33.5% from 25.1% YoY.
PAT rose 37.4% YoY to ₹11,805 Mn, even after accounting for a ₹4,266 Mn exceptional item.
India formulation sales grew 10.9% YoY, while Global API sales declined 24.1% YoY.
Net Cash position stands at ₹28,793 Mn with a Net Debt to Equity ratio of -0.14.
💼 Action for Investors
Investors should focus on the strong US growth and significant margin expansion as key positives. While API sales were weak, the company's robust cash position and leadership in US generics support a positive long-term outlook.
Lupin Q3 FY26 Results: Consolidated Revenue Up 24.3% YoY; Impacted by ₹6.34B Exceptional Charges
Lupin reported a strong operational performance for Q3 FY26 with consolidated revenue growing 24.3% YoY to ₹71,675.2 million. However, the bottom line was significantly impacted by exceptional items totaling ₹6,338.4 million, including a ₹4,493.9 million ($50M) provision for US antitrust litigation and a ₹1,348.1 million ($15M) settlement for Mirabegron ER Tablets. Excluding these one-time costs, standalone profit before tax grew 16% YoY to ₹15,017.8 million, reflecting healthy core business momentum despite regulatory and legal headwinds.
Key Highlights
Consolidated Revenue from operations increased 24.3% YoY to ₹71,675.2 million.
Standalone Profit before exceptional items and tax grew 16% YoY to ₹15,017.8 million.
Recognized a ₹4,493.9 million ($50 million) provision for settling class-action antitrust litigations in the US.
Agreed to a one-time settlement payment of ₹1,348.1 million ($15 million) for Mirabegron ER Tablets dispute.
Accounted for ₹496.4 million in incremental costs due to the implementation of New Labour Codes effective November 2025.
💼 Action for Investors
Investors should focus on the robust 24% revenue growth and operational margins while treating the legal provisions as necessary one-time costs to clear litigation overhangs. The stock may see short-term volatility due to the net profit dip, but the underlying business strength remains intact.
Lupin Settles Mirabegron Patent Dispute with Astellas for USD 90 Million
Lupin Limited and its US subsidiary have entered into a settlement and license agreement with Astellas Pharma to resolve patent litigation regarding the drug Mirabegron. Under the agreement, Lupin will pay Astellas a total of USD 90 million, which includes a USD 75 million prepaid option payment. Additionally, Lupin will pay a per-unit license fee for products sold through September 2027. This settlement is significant as it removes legal uncertainty and allows Lupin to continue marketing the product.
Key Highlights
Settlement resolves long-standing patent infringement dispute with Astellas Pharma regarding 'Mirabegron'.
Lupin to pay a total of USD 90 million, including a USD 75 million Prepaid Option Payment.
Agreement includes a Prepaid Per Unit License Fee for each unit sold through September 2027.
The settlement ensures Lupin can continue to sell its Mirabegron product without further litigation risk.
💼 Action for Investors
Investors should monitor the impact of the USD 90 million cash outflow on the upcoming quarterly earnings and margins. While the payout is substantial, the resolution of legal risk for a key product provides long-term clarity for the US generic portfolio.
Lupin Launches Topiramate Extended-Release Capsules in US; $164M Market Opportunity
Lupin Limited has launched Topiramate Extended-Release Capsules in the United States following U.S. FDA approval of its Abbreviated New Drug Application (ANDA). The product is a generic version of Trokendi XR® and is available in four strengths ranging from 25 mg to 200 mg. The addressable market for this product in the U.S. is estimated at USD 164 million annually according to IQVIA data. This launch strengthens Lupin's portfolio in the Central Nervous System (CNS) therapeutic segment, a key growth area for the company.
Key Highlights
Launched Topiramate Extended-Release Capsules in 25 mg, 50 mg, 100 mg, and 200 mg strengths.
Product is bioequivalent to the reference drug Trokendi XR® by Supernus Pharmaceuticals.
Estimated annual sales for the product in the U.S. market are USD 164 million as of December 2025.
Indicated for the treatment of seizures in patients 6 years and older and migraine prevention in patients 12 years and older.
💼 Action for Investors
Investors should monitor Lupin's ability to capture market share in the CNS segment, as this launch provides a steady revenue stream in the U.S. generics market. The $164 million market size offers a meaningful incremental growth opportunity for the company's North American operations.
Lupin Launches Generic Sprycel (Dasatinib) in US Targeting $930 Million Market
Lupin Limited has launched Dasatinib Tablets in the United States, a generic version of Bristol-Myers Squibb's Sprycel, following US FDA approval. Developed in partnership with Pharmascience Inc., the product is available in six strengths ranging from 20 mg to 140 mg. This launch addresses a significant market opportunity, as the reference drug Sprycel had estimated annual US sales of USD 930 million as of October 2025. The medication is used for treating Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in both adults and children.
Key Highlights
Launched Dasatinib Tablets in 20mg, 50mg, 70mg, 80mg, 100mg, and 140mg strengths in the US
Targets a market with estimated annual sales of USD 930 million (IQVIA MAT Oct 2025)
Product developed in collaboration with Canadian firm Pharmascience Inc.
Indicated for multiple leukemia treatments including Ph+ CML and Ph+ ALL in adults and pediatric patients
💼 Action for Investors
This high-value generic launch is expected to bolster Lupin's US revenue and oncology portfolio. Investors should track the company's ability to capture market share from the innovator and other generic entrants.
Lupin Partners with TB Alliance to Advance Telacebec for Tuberculosis and Mycobacterial Diseases
Lupin has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of Telacebec (formerly Q203). The drug targets major mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. While TB Alliance leads the development process, Lupin will leverage its global manufacturing expertise and distribution network across 100+ markets to ensure supply. This partnership strengthens Lupin's position in the anti-infective therapy area and addresses significant unmet medical needs globally.
Key Highlights
Strategic collaboration for Telacebec (Q203) targeting TB, leprosy, and Buruli ulcer
Lupin to provide global manufacturing, regulatory affairs, and supply chain expertise
TB Alliance to continue leading the clinical development process of the investigational drug
Lupin operates 15 manufacturing sites and 7 research centers to support global access
Collaboration aims to provide equitable access to advanced treatments in over 100 markets
💼 Action for Investors
Investors should monitor the clinical trial progress of Telacebec as it represents a significant addition to Lupin's anti-infective pipeline. This partnership enhances Lupin's long-term growth prospects in specialized therapy areas and its global ESG standing.
Lupin Achieves Highest Double 'A' ESG Rating from CDP for Climate and Water
Lupin Limited has been awarded the highest 'A' leadership rating by the Climate Disclosure Project (CDP) for both Climate Change and Water Security in 2026. This marks a steady improvement from its 2024 'A-' ratings and 2023 ratings of 'B' for climate and 'C' for water. Furthermore, the company reported an S&P Global ESG score of 91 for 2025, placing it in an elite global bracket of companies surpassing the 90-point threshold. These achievements reflect Lupin's enhanced focus on sustainability, which is increasingly vital for attracting global institutional capital.
Key Highlights
Achieved double 'A' leadership rating from CDP for Climate Change and Water Security in 2026.
Significant multi-year improvement from 2023 ratings of 'B' (Climate) and 'C' (Water).
Secured a best-in-class S&P Global ESG score of 91 in 2025.
Recognition positions Lupin as a global leader in environmental transparency and risk management.
💼 Action for Investors
Investors should view this as a positive fundamental development that enhances Lupin's attractiveness to ESG-mandated institutional funds. While it doesn't impact short-term earnings, it strengthens the company's long-term risk profile and global reputation.
Lupin Signs Licensing Deal with Galenicum for Semaglutide in 23 Global Markets
Lupin Limited has entered into a strategic licensing and supply agreement with Galenicum Health for injectable Semaglutide, a high-demand GLP-1 receptor agonist. The partnership covers 23 countries across Canada, Europe, Southeast Asia, and Latin America, positioning Lupin to capture growth in the global diabetes and obesity markets. While Galenicum will manage manufacturing and development, Lupin will leverage its commercial infrastructure for regulatory approvals and distribution. This move significantly strengthens Lupin's specialty portfolio and expands its international footprint in high-growth therapeutic areas.
Key Highlights
Agreement covers the commercialization of injectable Semaglutide in 23 countries globally.
Target markets include major regions such as Canada, Europe, Southeast Asia, and Latin America.
Lupin will handle all regulatory submissions, approvals, and distribution while Galenicum manages manufacturing.
Strategic entry into the GLP-1 market, which is currently one of the fastest-growing segments in pharma for diabetes and obesity.
Lupin's subsidiary, Lupin Atlantis Holdings SA (LAHSA), will execute the agreement.
💼 Action for Investors
Investors should view this as a strong strategic move into the lucrative GLP-1 market. Monitor the timeline for regulatory approvals and product launches in the specified 23 countries as these will be the primary drivers for future revenue growth from this deal.